Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33


Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk.

Schonberg MA, Li VW, Eliassen AH, Davis RB, LaCroix AZ, McCarthy EP, Rosner BA, Chlebowski RT, Hankinson SE, Marcantonio ER, Ngo LH.

Breast Cancer Res Treat. 2016 Dec;160(3):547-562.


Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer Patients.

Sherman ME, Ichikawa L, Pfeiffer RM, Miglioretti DL, Kerlikowske K, Tice J, Vacek PM, Gierach GL.

PLoS One. 2016 Aug 25;11(8):e0160966. doi: 10.1371/journal.pone.0160966.


Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older.

Schonberg MA, Li VW, Eliassen AH, Davis RB, LaCroix AZ, McCarthy EP, Rosner BA, Chlebowski RT, Rohan TE, Hankinson SE, Marcantonio ER, Ngo LH.

J Natl Cancer Inst. 2015 Nov 30;108(3). pii: djv348. doi: 10.1093/jnci/djv348.


Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis.

Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, Boffetta P, Weiss M.

Ann Oncol. 2015 Dec;26(12):2398-407. doi: 10.1093/annonc/mdv379. Review.


At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction.

Fusar-Poli P, Cappucciati M, Rutigliano G, Schultze-Lutter F, Bonoldi I, Borgwardt S, Riecher-Rössler A, Addington J, Perkins D, Woods SW, McGlashan TH, Lee J, Klosterkötter J, Yung AR, McGuire P.

World Psychiatry. 2015 Oct;14(3):322-32. doi: 10.1002/wps.20250.


Emerging Concepts in Breast Cancer Risk Prediction.

Gierach GL, Yang XR, Figueroa JD, Sherman ME.

Curr Obstet Gynecol Rep. 2013 Mar;2(1):43-52.


Association between oestrogens receptor expressions in breast cancer and comorbidities: a cross-sectional, population-based study.

de Decker L, Campone M, Retornaz F, Berrut G, Kabeshova A, Molinié F, Beauchet O.

PLoS One. 2014 May 21;9(5):e98127. doi: 10.1371/journal.pone.0098127.


Breast cancer risk in older women: results from the NIH-AARP Diet and Health Study.

Brinton LA, Smith L, Gierach GL, Pfeiffer RM, Nyante SJ, Sherman ME, Park Y, Hollenbeck AR, Dallal CM.

Cancer Causes Control. 2014 Jul;25(7):843-57. doi: 10.1007/s10552-014-0385-3.


Mammographic breast density as a risk factor for breast cancer: awareness in a recently screened clinical sample.

O'Neill SC, Leventhal KG, Scarles M, Evans CN, Makariou E, Pien E, Willey S.

Womens Health Issues. 2014 May-Jun;24(3):e321-6. doi: 10.1016/j.whi.2014.02.005.


Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.

Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A.

Epidemiol Rev. 2014;36:114-36. doi: 10.1093/epirev/mxt010. Review.


Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women.

Vogel VG.

Breast Cancer (Dove Med Press). 2011 Oct 20;3:127-37. doi: 10.2147/BCTT.S11288. Review.


Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.

Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW, Kristensen V, Anton-Culver H, Goodfellow P, Tapper WJ, Rafiq S, Gerty SM, Durcan L, Konstantopoulou I, Fostira F, Vratimos A, Apostolou P, Konstanta I, Kotoula V, Lakis S, Dimopoulos MA, Skarlos D, Pectasides D, Fountzilas G, Beckmann MW, Hein A, Ruebner M, Ekici AB, Hartmann A, Schulz-Wendtland R, Renner SP, Janni W, Rack B, Scholz C, Neugebauer J, Andergassen U, Lux MP, Haeberle L, Clarke C, Pathmanathan N, Rudolph A, Flesch-Janys D, Nickels S, Olson JE, Ingle JN, Olswold C, Slettedahl S, Eckel-Passow JE, Anderson SK, Visscher DW, Cafourek VL, Sicotte H, Prodduturi N, Weiderpass E, Bernstein L, Ziogas A, Ivanovich J, Giles GG, Baglietto L, Southey M, Kosma VM, Fischer HP; GENICA Network., Reed MW, Cross SS, Deming-Halverson S, Shrubsole M, Cai Q, Shu XO, Daly M, Weaver J, Ross E, Klemp J, Sharma P, Torres D, Rüdiger T, Wölfing H, Ulmer HU, Försti A, Khoury T, Kumar S, Pilarski R, Shapiro CL, Greco D, Heikkilä P, Aittomäki K, Blomqvist C, Irwanto A, Liu J, Pankratz VS, Wang X, Severi G, Mannermaa A, Easton D, Hall P, Brauch H, Cox A, Zheng W, Godwin AK, Hamann U, Ambrosone C, Toland AE, Nevanlinna H, Vachon CM, Couch FJ.

Carcinogenesis. 2014 May;35(5):1012-9. doi: 10.1093/carcin/bgt404.


Validation of a breast cancer risk prediction model developed for Black women.

Boggs DA, Rosenberg L, Pencina MJ, Adams-Campbell LL, Palmer JR.

J Natl Cancer Inst. 2013 Mar 6;105(5):361-7. doi: 10.1093/jnci/djt008.


Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study.

Pastor-Barriuso R, Ascunce N, Ederra M, Erdozáin N, Murillo A, Alés-Martínez JE, Pollán M.

Breast Cancer Res Treat. 2013 Feb;138(1):249-59. doi: 10.1007/s10549-013-2428-y.


Consumption of dairy and meat in relation to breast cancer risk in the Black Women's Health Study.

Genkinger JM, Makambi KH, Palmer JR, Rosenberg L, Adams-Campbell LL.

Cancer Causes Control. 2013 Apr;24(4):675-84. doi: 10.1007/s10552-013-0146-8.


Assessing risk of breast cancer in an ethnically South-East Asia population (results of a multiple ethnic groups study).

Gao F, Machin D, Chow KY, Sim YF, Duffy SW, Matchar DB, Goh CH, Chia KS.

BMC Cancer. 2012 Nov 19;12:529. doi: 10.1186/1471-2407-12-529.


Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).

Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Bandos H, Weissfeld JL, Wolmark N.

Cancer Prev Res (Phila). 2012 Nov;5(11):1321-9. doi: 10.1158/1940-6207.CAPR-12-0273.


Evaluating breast cancer risk projections for Hispanic women.

Banegas MP, Gail MH, LaCroix A, Thompson B, Martinez ME, Wactawski-Wende J, John EM, Hubbell FA, Yasmeen S, Katki HA.

Breast Cancer Res Treat. 2012 Feb;132(1):347-53. doi: 10.1007/s10549-011-1900-9.


Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials.

Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, Chlebowski RT.

Breast Cancer Res Treat. 2012 Feb;132(1):275-85. doi: 10.1007/s10549-011-1848-9.


Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Euhus D, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt K, Xia W, O'Shaughnessy J, Grant M, Arun B, Dooley W, Miller A, Flockhart D, Lewis C.

Cancer Prev Res (Phila). 2011 Nov;4(11):1852-62. doi: 10.1158/1940-6207.CAPR-11-0186.

Items per page

Supplemental Content

Support Center